Teleflex, a provider of medical devices for critical care and surgery, has secured FDA 510(k) clearance to market its Arrow JACC with Chlorag+ard Technology and TightTrack tunneler.
Arrow JACC with Chlorag+ard Technology is a long-term, tunneled, small french size antithrombogenic and antimicrobial central venous catheter intended to meet the requirements of patients throughout their course of therapy or illness.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Teleflex vascular division president Jay White said: “At Teleflex, we are committed to providing the right line for the right patient at the right time.
“We are proud to add the tunneled Arrow JACC to our line of vascular access products.
“By providing an antithromogenic and antimicrobial catheter that protects against catheter occlusion, we are offering a technology that no one else can.
“This is especially important in patients with end stage renal disease where vessel health and preservation is essential to provide a future dialysis vascular access.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFurther, the catheter is also meant for use with high-pressure injection for diagnostic studies.
The Arrow JACC with Chlorag+ard Technology protects against catheter occlusion, phlebitis, and intimal hyperplasia for up to 30 days.
This device enables caregivers to effectively and economically preserve vessel access, and care for millions of end stage renal disease patients.
